All News

Covid lung pneumonia corona (keep)

Tofacitinib Efficacy in COVID-19 Pneumonia

Jack Cush, MD

NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.

Read Article
yes, no, maybe

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

Janet Pope, MD, MPH, FRCPC

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021.

Read Article
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Jack Cush, MD

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
PSA068.jpg

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Meral K. El Ramahi, MD, FACP, FACR

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

RA after 70: Too Old for bioDMARDs?

Aurelie Najm, MD, PhD

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.

Read Article
When should you use a JAK inhibitor in RA? Dr. Janet Pope ( @Janetbirdope ) shares #EULAR2021 presentations. https://t.co/qF2tjQXLk1 https://t.co/AqJ1dMWV3t

Links:

Dr. John Cush RheumNow ( View Tweet)
Do Patients on Upadacitinib Need Labs? Dr. Janet Pope from Canada, discusses abstract OP00128 presented at the virtual #EULAR2021. https://t.co/mxPzeQXZk7 https://t.co/qz9KiYfTCu

Links:

Dr. John Cush RheumNow ( View Tweet)
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more... https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC) Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021. https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui

Links:

Dr. John Cush RheumNow ( View Tweet)
@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT

Links:

EnvisionRheumat ERheumat ( View Tweet)
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

tyk2 makes sense to inhibit in PsA. Part of kinase family including JAK/TYK2, TYK2 is ⬆️in PsA. Deficiency of TYK2 gives less autoimmune diseases. @RheumNow @eular_org #EULAR2021 BMS Tyk Talk symposium https://t.co/knP9n0Qc0u

Janet Pope Janetbirdope ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu

Links:

Dr. John Cush RheumNow ( View Tweet)
Looking at those results (distributed evenly each side of 'maybe a little') it seems we're collectively uncertain right now about what JAK1 selectivity really means in practice. Hopefully we get stronger clinical insights (toxicity/efficacy) in coming years! #EULAR2021 @RheumNow https://t.co/jFhVGqpOnb

Links:

David Liew drdavidliew ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari >Adalimumab for pain, HAQ, am stiffness but = on fatigue. POS0649 @RheumNow @eular_org #EULAR2021

Janet Pope Janetbirdope ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×